AVID Medical Recalls Transport Bag Kit Over Sterility Risk
AVID Medical recalled 1,500 units of the TRANSPORT BAG KIT on January 2, 2026. A seal issue with the Tyvek bag may compromise the sterility of the kit. The recall affects healthcare providers and patients in New Jersey.
Quick Facts at a Glance
Recall Date
January 2, 2026
Hazard Level
HIGH
Brand
AVID Medical
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL
Hazard Information
Tyvek bag seal issue which may compromise sterility of the kit.
What You Should Do
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact AVID Medical, Inc. or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
Product Details
The recalled product is the Halyard TRANSPORT BAG KIT, Kit Code: LIFE0080-01, with UDI-DI: 10809160314500 and Lot Number: 1650056. The expiration date is July 24, 2028. The kits were distributed nationwide, primarily in New Jersey.
The Hazard
The recall stems from a Tyvek bag seal issue which may compromise the sterility of the kit. This defect poses a high risk as it can lead to infections or other complications for patients.
Reported Incidents
There are no reported incidents or injuries associated with this recall at this time. Consumers should remain vigilant and monitor any symptoms that might arise.
What to Do
Stop using the product immediately. Follow recall instructions provided by AVID Medical, Inc. or contact your healthcare provider for further guidance.
Contact Information
For more information, contact AVID Medical, Inc. via email. More details can be found on the FDA website.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.